Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2313533
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSK2313533 is an investigational compound developed by GSK and investigated in early-phase clinical trials as part of a portfolio of related molecules[1]. Available records indicate it is being studied in healthy volunteers for its safety, tolerability, pharmacokinetics, and pharmacodynamics, likely as a small molecule. The precise mechanism of action, molecular target, and intended indication are not described in the accessible clinical trial documentation[1]. There is insufficient public information regarding its molecular structure, therapeutic class, or clinical application.
- Brand names
- GSK2313533GSK-2313533GSK 2313533
- Other names
- GSK2313533GSK-2313533GSK 2313533
Beyond the preview
Go deeper on GSK2313533.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2313533.